<Anchor>



Yesterday (21st) there were 61 new confirmed cases of Corona 19, maintaining double digits for three consecutive days.

When looking at the domestic outbreak alone, the number of confirmed cases in the metropolitan area is continuing to decline to 51, and as we watch the spread as if receiving a report card every day, we wonder when the corona vaccine will come out.

The development competition is in full swing all over the world, and China is the most advanced based on claims alone.



There were no clinical side effects, and it is possible to release it at the end of the year, so Beijing Coronavirus correspondent Songwook pointed out how reliable it is.



<Reporter> This



is the vaccine production facility of China's state-run pharmaceutical company'Sinopharm' in Beijing.



It aims to produce 200 million pieces of COVID-19 vaccine per year.



Sinoparm said that the Corona 19 vaccine is likely to be released at the end of this year, and the price will be around 100,000 won.



There are 36 types of Corona 19 vaccines that have entered the clinical stage around the world, of which 11 are Chinese vaccines.



In particular, out of 9 vaccines that have entered the final phase of clinical trials, 4 are made in China.



South America, the Middle East, and Southeast Asian countries, where quarantine is urgently needed, have spread their hands towards the fast-paced Chinese vaccine.



China has conducted phase 3 trials in these countries, while also inoculating over 350,000 people in China.



As a result, they claimed that there were no side effects or cases of infection.



[Yang Xiao-ming/CEO of Sino Pharm, China: So far, it has been very good in terms of safety.

Basically, there wasn't one side effect.] The



question is, can you just believe this claim.



Side effects are reported one after another in the clinical trials of pharmaceutical companies in the UK and the US, which have disclosed the clinical trial plan and details in detail, but the Chinese vaccine development, which did not disclose the data, is somewhat too smooth.



Some point out that it is a credibility issue that China cannot but endure, which did not disclose the situation transparently in the early days of the Corona 19 outbreak.



(Video coverage: Ma Kyu, video editing: Oh No-young)